Business
China Resources Sanjiu Medical & Pharmaceutical Co: Revenue surged but profit declined as acquisition and investment costs rose sharply
China Resources Sanjiu Medical & Pharmaceutical Co: Revenue surged but profit declined as acquisition and investment costs rose sharply
About this update from China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Class A
Q3 2025 revenue grew 27.37% year-over-year, but net profit fell 4.26% and year-to-date profit dropped 20.51%. The Tian Shi Li acquisition drove major asset and liability increases, while higher R&D and financing costs pressured margins.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.